At Alkermes, we apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized. Our greatest strengths at Alkermes are our people and our inherent empathy for patients, families and caregivers. Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We work with urgency to develop new treatment options for people living with these conditions. Beyond our important mission of developing medicines, we believe it is our responsibility to take a holistic approach as we seek to support patients, caregivers and broader impacted communities. We remain committed to patient engagement, responsible and sustainable operations, and equitable access to quality treatment. Headquartered in Dublin, Ireland, we have an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. See our Community Guidelines: https://www.alkermes.com/social-community-guidelines
View Top Employees from AlkermesWebsite | https://www.alkermes.com/ |
Ticker | ALKS |
Revenue | $1.2 billion |
Funding | $251.2 million |
Employees | 2,533 (2,533 on RocketReach) |
Founded | 1987 |
Address | Connaught House 1 Burlington Rd, Dublin, Leinster D04 C5Y6, IE |
Phone | +353 1 772 8000 |
Technologies |
JavaScript,
HTML,
Twitter
+184 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Healthcare |
Competitors | Acadia Pharmaceuticals Inc., Amarin Corporation, Avanir Pharmaceuticals, Nektar Therapeutics, Regeneron |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 541711 Companies, NAICS Code 62 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 6215 Companies, NAICS Code 621 Companies, NAICS Code 5417 Companies, NAICS Code 62151 Companies |
Looking for a particular Alkermes employee's phone or email?
The Alkermes annual revenue was $1.2 billion in 2024.
Elspeth Carnan is the Senior Vice President of Clinical Development Operations of Alkermes.
2,533 people are employed at Alkermes.
Alkermes is based in Dublin, Leinster.
The NAICS codes for Alkermes are [54171, 541711, 62, 54, 541, 6215, 621, 5417, 62151].
The SIC codes for Alkermes are [283, 28].